Can a pill keep mantle cell lymphoma away? new study tests ibrutinib maintenance
NCT ID NCT02242097
First seen Jun 12, 2026 · Last updated Jun 21, 2026 · Updated 1 time
Summary
This study tested whether the drug ibrutinib can safely keep mantle cell lymphoma from returning after initial chemotherapy. Thirty-seven patients who had already responded to chemo took ibrutinib as a maintenance therapy. Researchers tracked how long patients stayed cancer-free and what side effects occurred.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONTIGUOUS STAGE II MANTLE CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Northwestern University- Lake Forest Hospital
Lake Forest, Illinois, 60045, United States
-
University of Utah
Salt Lake City, Utah, 84132, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ibrutinib
What this could lead to
If it works, this could offer a way to keep mantle cell lymphoma from coming back longer after initial treatment.
What could go wrong
This is a small, early-phase study (37 people) with no comparison group, so results may not be definitive. Ibrutinib can cause side effects like bleeding, infection, or heart issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.